
Clinicians' Guides to Radionuclide Hybrid Imaging

PET/CT

Series Editors

Jamshed B. Bomanji
London, UK

Gopinath Gnanasegaran
London, UK

Stefano Fanti
Bologna, Italy

Homer A. Macapinlac
Houston, Texas, USA

More information about this series at <http://www.springer.com/series/13803>

Francesco Fraioli
Editor

PET/CT in Brain Disorders

 Springer

 **BNMS**
BRITISH NUCLEAR MEDICINE SOCIETY

Editor

Francesco Fraioli
Institute of Nuclear Medicine
University College London
London
UK

ISSN 2367-2439 ISSN 2367-2447 (electronic)
Clinicians' Guides to Radionuclide Hybrid Imaging - PET/CT
ISBN 978-3-030-01522-0 ISBN 978-3-030-01523-7 (eBook)
<https://doi.org/10.1007/978-3-030-01523-7>

Library of Congress Control Number: 2018964423

© Springer Nature Switzerland AG 2019

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

*PET/CT series is dedicated to Prof Ignac
Fogelman, Dr Muriel Buxton-Thomas and
Prof Ajit K Padhy*

Foreword

Clear and concise clinical indications for PET/CT in the management of the oncology and non-oncology patient are presented in this series of 15 separate booklets.

The impact on better staging, tailored management and specific treatment of the patient with cancer has been achieved with the advent of this multimodality imaging technology. Early and accurate diagnosis will always pay, and clear information can be gathered with PET/CT on treatment responses. Prognostic information is gathered and can forward guide additional therapeutic options.

It is a fortunate coincidence that PET/CT was able to derive great benefit from radionuclide-labelled probes, which deliver good and often excellent target to non-target signals. Whilst labelled glucose remains the cornerstone for the clinical benefit achieved, a number of recent probes are definitely adding benefit. PET/CT is hence an evolving technology, extending its applications and indications. Significant advances in the instrumentation and data processing available have also contributed to this technology, which delivers high throughput and a wealth of data, with good patient tolerance and indeed patient and public acceptance. As an example, the role of PET/CT in the evaluation of cardiac disease is also covered, with emphasis on labelled rubidium and labelled glucose studies.

The novel probes of labelled choline; labelled peptides, such as DOTATATE; and, most recently, labelled PSMA (prostate-specific membrane antigen) have gained rapid clinical utility and acceptance, as significant PET/CT tools for the management of neuroendocrine disease and prostate cancer patients, notwithstanding all the advances achieved with other imaging modalities, such as MRI. Hence a chapter reviewing novel PET tracers forms a part of this series.

The oncological community has recognised the value of PET/CT and has delivered advanced diagnostic criteria for some of the most important indications for PET/CT. This includes the recent Deauville criteria for the classification of PET/CT patients with lymphoma—similar criteria are expected to develop for other malignancies, such as head and neck cancer, melanoma and pelvic malignancies. For completion, a separate section covers the role of PET/CT in radiotherapy planning, discussing the indications for planning biological tumour volumes in relevant cancers.

These booklets offer simple, rapid and concise guidelines on the utility of PET/CT in a range of oncological indications. They also deliver a rapid aide-memoire on the merits and appropriate indications for PET/CT in oncology.

London, UK

Peter J. Ell, FMedSci, DR HC, AQA

Preface

The *Hybrid Imaging* with PET/CT and SPECT/CT combines the best of function and structure to provide accurate localisation, characterisation and diagnosis. There is extensive literature and evidence to support PET/CT, which has made significant impact in oncological imaging and management of patients with cancer. The evidence in favour of SPECT/CT especially in orthopaedic indications is evolving and increasing.

The *Clinicians' Guides to Radionuclide Hybrid Imaging* pocketbook series is specifically aimed at our referring clinicians, nuclear medicine/radiology doctors, radiographers/technologists and nurses who are routinely working in nuclear medicine and participate in multidisciplinary meetings. This series is the joint work of many friends and professionals from different nations who share a common dream and vision towards promoting and supporting nuclear medicine as a useful and important imaging speciality.

We want to thank all those people who have contributed to this work as advisors, authors and reviewers, without whom the book would not have been possible. We want to thank our members from the BNMS (British Nuclear Medicine Society, UK) for their encouragement and support, and we are extremely grateful to Dr. Brian Nielly, Charlotte Weston, the BNMS Education Committee and the BNMS Council Members for their enthusiasm and trust.

Finally, we wish to extend particular gratitude to the industry for their continuous supports towards education and training.

London, UK

Gopinath Gnanasegaran
Jamshed B. Bomanji

Acknowledgements

The series co-ordinators and editors would like to express sincere gratitude to the members of the British Nuclear Medicine Society, patients, teachers, colleagues, students, the industry and the BNMS Education Committee Members, for their continued support and inspiration.

Andy Bradley
Brent Drake
Francis Sundram
James Ballinger
Parthiban Arumugam
Rizwan Syed
Sai Han
Vineet Prakash

Contents

1	Introduction to Brain Disorders	1
	Jamshed Bomanji and Francesco Fraioli	
2	Radiological Imaging in Brain Disorders: An Overview	3
	Valentina Ferrazzoli and Kshitij Mankad	
3	PET Tracers for Brain Imaging	15
	Christine Tang and Vincenzo Militano	
4	¹⁸F-FDG PET/CT: Brain Imaging	23
	April-Louise Smith and Anna Barnes	
5	¹⁸F-FDG-PET/CT (FDG-PET) in Neurodegenerative Disease	37
	Selene Capitanio, Matteo Bauckneht, Dario Arnaldi, Federico Massa, Riccardo Meli, Valentina Ceriani, Flavio Nobili, and Silvia Morbelli	
6	[¹⁸F]FDG-PET/CT in Movement Disorders	49
	Patrik Fazio and Andrea Varrone	
7	¹⁸F-FDG PET in Epilepsy	65
	Ismeni C. Mainta, Fabienne Picard, and Valentina Garibotto	
8	PET in Neuro-Oncology	77
	Francesco Fraioli	
9	¹⁸F-FDG PET/CT Indications, Pitfalls and Limitations in Brain Imaging	91
	Stefan Vöö and Jamshed Bomanji	
10	Clinical Applications of Non-¹⁸F-FDG PET/CT Tracers in Brain Imaging	103
	Vincenzo Militano, Christine Tang, Demetrio Arico', and Claudio Giardina	
11	Amyloid-β PET Imaging in Aging and Dementia	119
	Nelleke Tolboom, Rik Ossenkoppele, and Bart N. van Berckel	

12	The Use of PET/CT in Radiotherapy Planning for Brain Tumours. . .	131
	Francesca Soldá and Naomi Fersht	
13	Clinical Applications of PET/MRI in Brain Imaging	145
	Francesco Fraioli and Karar Obeed Almansory	
14	Clinical Atlas of Brain PET/CT.	155
	Khulood Al Riyami and Francesco Fraioli	
	Index.	175

Contributors

Karar Obeed Almansory Institute of Nuclear Medicine, University College London Hospital, London, UK

Khulood Al Riyami Institute of Nuclear Medicine, University College of London Hospital, London, UK

Demetrio Arico Department of Nuclear Medicine, Humanitas Oncological Centre of Catania, Catania, Italy

Dario Arnaldi Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Mother-Child Health (DINOEMI), Clinical Neurology, Polyclinic San Martino Hospital, University of Genoa, Genoa, Italy

Anna Barnes Institute of Nuclear Medicine, University College London Hospital NHS Foundation Trust, London, UK

Matteo Bauckneht Department of Health Sciences (DiSSAL), University of Genoa and Nuclear Medicine Unit, Polyclinic San Martino Hospital, Genoa, Italy

Jamshed B. Bomanji Institute of Nuclear Medicine, University College London Hospitals NHS Foundation Trust, London, UK

Selene Capitano Department of Health Sciences (DiSSAL), University of Genoa and Nuclear Medicine Unit, Polyclinic San Martino Hospital, Genoa, Italy

Valentina Ceriani Department of Health Sciences (DiSSAL), University of Genoa and Nuclear Medicine Unit, Polyclinic San Martino Hospital, Genoa, Italy

Patrik Fazio Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden

Department of Neurology, Karolinska University Hospital, Stockholm, Sweden

Valentina Ferrazzoli Department of Biomedicine and Prevention, Tor Vergata University Hospital, Rome, Italy

Naomi Fersht Department of Oncology, University College Hospital, London, UK

Francesco Fraioli Institute of Nuclear Medicine, University College London, London, UK

Valentina Garibotto Nuclear Medicine and Molecular Imaging Division, Department of Medical Imaging, University Hospitals of Geneva, Geneva, Switzerland

Faculty of Medicine, Geneva University, Geneva, Switzerland

Claudio Giardina Department of Radiology, ASP of Messina–Hospital of Taormina, Taormina, ME, Italy

Ismi C Mainta Nuclear Medicine and Molecular Imaging Division, Department of Medical Imaging, University Hospitals of Geneva, Geneva, Switzerland

Faculty of Medicine of Geneva University, Geneva, Switzerland

Kshitij Mankad Department of Radiology, Great Ormond Street Hospital NHS Foundation Trust, London, UK

Federico Massa Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Mother-Child Health (DINO GMI), Clinical Neurology, Polyclinic San Martino Hospital University of Genoa Genoa, Genoa, Italy

Riccardo Meli Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Mother-Child Health (DINO GMI), Clinical Neurology, Polyclinic San Martino Hospital, University of Genoa, Genoa, Italy

Vincenzo Militano Institute of Nuclear Medicine, University College of London Hospital, London, UK

Silvia Morbelli Department of Health Sciences (DiSSAL), University of Genoa and Nuclear Medicine Unit, Polyclinic San Martino Hospital, Genoa, Italy

Flavio Nobili Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, and Mother-Child Health (DINO GMI), Clinical Neurology, Polyclinic San Martino Hospital, University of Genoa, Genoa, Italy

Rik Ossenkoppele Alzheimer center, Amsterdam University Medical Center, Amsterdam, The Netherlands

Clinical Memory Research Unit, Lund University, Lund, Sweden

Fabienne Picard Faculty of Medicine of Geneva University, Geneva, Switzerland
EEG and Epilepsy Unit, Neurology Department, University Hospitals of Geneva, Geneva, Switzerland

April-Louise Smith Institute of Nuclear Medicine, University College London Hospital NHS Foundation Trust, London, UK

Francesca Soldá Department of Oncology, University College Hospital, London, UK

Christine Tang Institute of Nuclear Medicine, University College of London Hospital, London, UK

Nelleke Tolboom Nuclear Medicine Physician, Department of Radiology (Imaging Division), University Medical Center Utrecht, Utrecht, The Netherlands

Bart N. van Berckel Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands

Andrea Varrone Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden

Stefan Vöö Institute of Nuclear Medicine, University College of London Hospital, London, UK